suramin has been researched along with Muscular Dystrophy, Duchenne in 4 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Muscular Dystrophy, Duchenne: An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)
Excerpt | Relevance | Reference |
---|---|---|
"Severe muscle fibrosis is the endpoint of many chronic myopathies." | 1.39 | Duchenne muscular dystrophy fibroblast nodules: a cell-based assay for screening anti-fibrotic agents. ( Gibertini, S; Mantegazza, R; Mora, M; Savadori, P; Zanotti, S, 2013) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
De Oliveira Moreira, D | 1 |
Pereira, JA | 1 |
Taniguti, AP | 2 |
Matsumura, CY | 2 |
Ramos, LA | 1 |
Areas, MA | 1 |
Neto, HS | 1 |
Marques, MJ | 2 |
Zanotti, S | 1 |
Gibertini, S | 1 |
Savadori, P | 1 |
Mantegazza, R | 1 |
Mora, M | 1 |
Fairclough, RJ | 1 |
Perkins, KJ | 1 |
Davies, KE | 1 |
Rodrigues-Simioni, L | 1 |
Santo Neto, H | 1 |
1 review available for suramin and Muscular Dystrophy, Duchenne
Article | Year |
---|---|
Pharmacologically targeting the primary defect and downstream pathology in Duchenne muscular dystrophy.
Topics: Aminoglycosides; Antigens, CD; Codon, Nonsense; Dystrophin; Gene Expression; Genetic Therapy; Humans | 2012 |
3 other studies available for suramin and Muscular Dystrophy, Duchenne
Article | Year |
---|---|
Suramin attenuates dystrophin-deficient cardiomyopathy in the mdx mouse model of duchenne muscular dystrophy.
Topics: Age Factors; Analysis of Variance; Animals; Antineoplastic Agents; Cardiomyopathies; Creatine Kinase | 2013 |
Duchenne muscular dystrophy fibroblast nodules: a cell-based assay for screening anti-fibrotic agents.
Topics: Biological Assay; Blotting, Western; Collagen; Decorin; Drug Evaluation, Preclinical; Enzyme-Linked | 2013 |
Suramin affects metalloproteinase-9 activity and increases β-dystroglycan levels in the diaphragm of the dystrophin-deficient mdx mouse.
Topics: Animals; Diaphragm; Dystroglycans; Dystrophin; Enzyme Activation; Female; Fibrosis; Male; Matrix Met | 2012 |